Found this info on a stand up to cancer web site. The priming ability was discovered with dacogen and vidaza. Also seen with second generation drugs (aka sgi-110, we hope). The recent discussion in Time Magazine may mean that they are able to repeat this on off switch. After two/four cycles they are seeing long term benefits. What would really benefit ASTX shares would be solid finding from the Dream team. You couldn't buy this much free press, that would follow. Here is the info:
Develop a clinical trial that utilizes a new second generation epigenetic drug that may be able to more effectively inhibit the epigenetic changes involved in cancer causation.
This SU2C Dream Team has tested a combination of epigenetic drugs in clinical trials and saw tumors shrink in a group of patients with non-small cell lung cancer, who had previously been treated, unsuccessfully, with three different chemotherapy regimens. More importantly, the team made the intriguing observation that multiple patients who were required to stop therapy after only two to four cycles have long survival periods and several are alive years after completion of these courses. These finding suggest that very short courses of the two epigenetic drugs used may have a lasting effect, and “prime” cancer cells to better respond to subsequent therapies such as cytotoxic chemotherapy, or immunotherapy. The Dream Team also reported success in a clinical trial testing a new generation of epigenetic drug in patients with leukemia, which prompted them to explore the possibility of conducting additional trials in solid tumors. The Dream Team is currently conducting clinical trials in breast, colon and lung cancers as well leukemia.